The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

A study published in Journal of American Geriatrics Society on Wednesday finds that older adults face lower odds for depression if they didn’t have depression earlier in life or had higher income ...

Older adults who had a negative history of depression or had ... The Patient-Reported Outcomes Measurement Information System (PROMIS®) depression scale was used to determine the depression status.

Marked variation in the prevalence of depression was found in a multisite sample of community-dwelling older adults in the United States, reports a study by Columbia University Mailman School of ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.